For each isolate, a suspension in the broth was prepared from an agar medium with 1 0 9 adequate growth of the isolate and the inoculum was standardized for susceptibility 1 1 0 testing to a turbidity equivalent to a 0.5 McFarland standard. Suspensions were 1 1 1 then diluted and inoculated into 96-well microtiter plates to achieve a final 1 1 2 organism concentration from 1 × 10 5 to 5 × 10 5 CFU/ml. The antimicrobial agent 1 1 3 minimum inhibitory concentrations (MICs) were interpreted according to the 1 1 4 guidelines established by the CLSI [13] . Serial double dilutions of antimicrobial 1 1 5 agents were prepared ranging from 0.06 to 512 mg/L, added to cation-1 1 6
supplemented Mueller-Hinton broth plus 5% OADC, and then 0.1 ml was 1 1 7 dispensed into the wells of microdilution plates. Following inoculation, all cultures 1 1 8
were incubated aerobically at 37 °C. Growth was examined weekly up to 4 weeks. The MIC was defined as the lowest concentration of the drug that inhibited visible 1 2 0 growth. Quality control of MICs was performed by testing recommended reference to ofloxacin (80%). Susceptibility to ofloxacin was only noted in the 5 isolates. In 1 3 5 vitro susceptibility to first-line anti-TB drugs was not found among clinical isolates 1 3 6 of M. simiae. Acquired resistance, defined as a resistant follow-up isolate after a 1 3 7 susceptible primary isolate, was noted in 10 patients; acquired rifampicin 1 3 8 resistance was most frequent, followed by acquired and isoniazid resistance. but the ecology behind this is not well understood [17] . We hypothesize that the 1 4 7 high rate of M. simiae in Iran may be due to the contamination of water supplies 1 4 8 with this pathogen, a finding that was previously reported in studies conducted in 1 4 9
Iran [18, 19] . Temperature and humidity have also been reported to be associated 1 5 0 with NTM infections [16, 20] . Another explanatory factor may be the presence of Another issue raised by M. simiae pulmonary disease is its difficulty in treatment. Since little is known about drug susceptibility patterns of clinical isolates of M. regimens. Based on our study, all M. simiae species showed resistance to isoniazid, showed resistant rates of 86% to amikacin, 77% to ciprofloxacin, 36% to France, M. simiae isolates were found to have low susceptibility to antibiotics, This study has some limitations. First, the small numbers of evaluated patients and In conclusions, clinical isolates of M. simiae were multidrug resistant and had 1 7 5 different drug susceptibility patterns than previously published studies. DST results 1 7 6
can assist in selecting more appropriate treatment regimens. Newer drugs with There is no conflict of interest. (100) 
